Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease
Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer's disease (AD) based on tau pathology. Abnormal aggregation of tau proteins is one of t...
Saved in:
Main Authors: | Caitlin V. M. L. Jie (Author), Valerie Treyer (Author), Roger Schibli (Author), Linjing Mu (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Potential PET tracers for imaging of tumor-associated macrophages
by: Bruna Fernandes, et al.
Published: (2022) -
Neuronal Vulnerability of the Entorhinal Cortex to Tau Pathology in Alzheimer's Disease
by: Simi Zhang, et al.
Published: (2024) -
PET Imaging in Cardiac Sarcoidosis: A Narrative Review with Focus on Novel PET Tracers
by: Petar Saric, et al.
Published: (2021) -
Findings of 18F‐PI‐2620 tau PET imaging in patients with Alzheimer's disease and healthy controls in relation to the plasma P‐tau181 levels in a Japanese sample
by: Shogyoku Bun, et al.
Published: (2022) -
An updated radiosynthesis of [18F]AV1451 for tau PET imaging
by: Andrew V. Mossine, et al.
Published: (2017)